J. Mestan

PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.

J M Wood, Guido Bold, Elisabeth Buchdunger et al. · PubMed · 2000 · 847 citations

Medicine, Oncology, Pharmacology +16

Vascular Endothelial Growth Factor (VEGF) Receptor-2 Antagonists Inhibit VEGF- and Basic Fibroblast Growth Factor-Induced Angiogenesis in Vivo and in Vitro

JC Tille, J M Wood, Stefano J. Mandriota et al. · Journal of Pharmacology and Experimental Therapeutics · 2001 · 127 citations

Medicine, Pharmacology, Cancer Pharmacology +14

Differential phosphoprofiles of EGF and EGFR kinase inhibitor-treated human tumor cells and mouse xenografts

David R. Stover, Jennifer Caldwell, Jarrod A. Marto et al. · Clinical Proteomics · 2004 · 27 citations · Full text

Medicine, Cancer Biology, Oncology +14

CGP 79787D (PTK787/ZK222584), CGP 84738, NVP-AAC789, NVP-AAD777 and related 1-anilino-(4-pyridylmethyl)phthalazines as inhibitors of VEGF- and bFGF-induced angiogenesis

Guido Bold, Joerg Frei, Pascal Furet et al. · Drugs of the Future · 2002 · 18 citations

Medicine, Medicinal Chemistry, Pharmacology +16

NVP-TAE226, a potent dual FAK/IGF-IR kinase inhibitor, prevents breast cancer metastasis in vivo

Ei Kawahara, Osamu Ohmori, K. Nonomura et al. · Journal of Clinical Oncology · 2006 · 10 citations

Medicine, Cancer Biology, Oncology +17